GSK Overview

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

Wall Street analysts forecast GSK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

GSK plc revenue for the last quarter amounts to 11.46B USD, increased 10.24

GSK plc. EPS for the last quarter amounts to 0.21 USD, increased 61.54

GSK plc (GSK) has 66841 emplpoyees as of March 11 2026.

Today GSK has the market capitalization of 110.85B USD.